Biomedical subjects

Hélio Elkis

Publications and source records attributed to Hélio Elkis.

5 recordsLinked to original sources

PubMed2006

Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia.

Typical antipsychotics have a high affinity for dopamine receptors. It is therefore of interest to investigate such loci in pharmacogenetic studies on psychosis. We investigated the hypothesis that Ser9Gly polymorphism of the DRD3 gene may play a role in the differences in individual response to typical antipsychotics between schizophrenic patients. The sample was composed of 53 good responders and 59 poor ones. No significant differences between the good and poor responders were found in the allelic distribution (good responders: Ser9 61.32%, Gly9 38.67%; poor responders: Ser9 64.40%, Gly9 35.59%; odds ratio, OR = 0.88, 0.49 < OR < 1.56; chi2 = 0.23, 1 degree of freedom, df, p = 0.63) and genotype distribution (good responders: Ser9/Ser9 37.73%, Ser9/Gly9 47.16%, Gly9/Gly9 15.09%; poor responders: Ser9/Ser9 42.37%, Ser9/Gly9 44.06%, Gly9/Gly9 13.55%; chi2 = 0.25, 2 df, p = 0.88). Nor was there any association with homozygosity (good responders: homozygous: 52.82%, heterozygous: 47.16%; poor responders: homozygous: 55.92%, heterozygous: 44.06%; odds ratio, OR = 0.88, 0.39 < OR < 1.99; chi2 = 0.11, 1 df, p = 0.74). The results did not support the hypothesis that Ser9Gly polymorphism of the DRD3 gene influences the response to typical antipsychotics in our sample of schizophrenics.

Alleles↗

PubMed2006

Structural brain abnormalities in early-onset schizophrenia.

BACKGROUND: Few studies investigated brain abnormalities in early onset schizophrenia. OBJECTIVE: To assess computed tomography (CT) abnormalities in patients with childhood or adolescence onset schizophrenia. METHOD: CT scans of patients with childhood (6 to 11 years old) (N=6) or adolescence (12-17 years old) (N=9) schizophrenia were compared to normal controls. Patients were diagnosed based on the DSM-III-R criteria. Ventricular enlargement was measured by the Ventricle to Brain Ratio (VBR) and Cortical Atrophy (pre-frontal prominence) was measured by the Pre-Frontal Atrophy Index (PFAI). RESULTS: There was a significant difference in VBR, but not in PFAI, between subjects and controls [8.26+/-2.79, and 5.71+/-3.26 (p=0.029)], and [2.72+/-1.77, and 3.21+/-1.53 (p=0.424)], respectively. There were no differences of VBR and PFAI between children and adolescents with schizophrenia. CONCLUSION: Compared to controls, patients with child or adolescent onset schizophrenia exhibit more pronounced ventricular enlargement. There were no differences regarding prefrontal atrophy.

Adolescent↗

PubMed2005

Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia.

BACKGROUND: Treatment noncompliance among schizophrenic patients is as high as 50%. In order to rate compliance and assess the most significant differences between compliant and noncompliant patients, a Brazilian population of schizophrenic outpatients was followed for one year. METHODS: Fifty outpatients were selected. Clinical interview, the Brief Psychiatric Rating Scale--Anchored version (BPRS-A) and an expanded version of the Rating of Medical Influences (ROMI) scale (used to rate patient attitudes toward compliance) were applied at baseline. The BPRS-A was used in the follow-up visits (approximately once a month). Missing two consecutive appointments without explanation or taking less than 75% of the medication (by written family report) was considered noncompliance. RESULTS: Noncompliance was 48% over one year. Patients in the noncompliant group presented initial worsening of psychotic symptoms (p < 0.05) and had been treated for a shorter length of time (p = 0.007). The ROMI scale showed that "perceived day-to-day benefit" was most strongly correlated with compliance, and feeling "distressed by side effects" was most strongly correlated with noncompliance. DISCUSSION: This study evaluates the frequency of noncompliance and the main reasons for complying in a population of schizophrenic outpatients. CONCLUSIONS: Severity of psychopathology was found to correlate with noncompliance (although not necessarily as its cause), as well as with duration of treatment. Noncompliance rates are high and must be taken into account in any treatment program.

Adolescent↗

PubMed2005

The psychopathological factors of refractory schizophrenia.

OBJECTIVES: The heterogeneity of clinical manifestations in schizophrenia has lead to the study of symptom clusters through psychopathological assessment scales. The objective of this study was to elucidate clusters of symptoms in patients with refractory schizophrenia which may also help to assess the patients' therapeutical response. METHODS: Ninety-six treatment resistant patients were evaluated by the anchored version Brief Psychiatric Rating Scale (BPRS-A) as translated into Portuguese. The inter-rater reliability was 0.80. The 18 items of the BPRS-A were subjected to exploratory factor analysis with Varimax rotation. RESULTS: Four factors were obtained: Negative/Disorganization, composed by emotional withdrawal, disorientation, blunted affect, mannerisms/posturing, and conceptual disorganization; Excitement, composed of excitement, hostility, tension, grandiosity, and uncooperativeness, grouped variables that evoke brain excitement or a manic-like syndrome; Positive, composed of unusual thought content, suspiciousness, and hallucinatory behavior; and Depressive, composed of depressive mood, guilt feelings, and motor retardation, clearly related to depressive syndrome. CONCLUSIONS: The study reproduced the four factors described in the literature, either in refractory or non-refractory patients. The BPRS-A allowed the distinction of psychopathological factors, which are important in the evaluation of treatment response of patients with schizophrenia.

Adult↗

PubMed2004

Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study.

In a double-blind, placebo controlled study, conjugated estrogens (CE) (0.625 mg/day) were added to a fixed dosage of haloperidol (5 mg daily). Forty-four female inpatients with acute schizophrenia were included in the study and randomized to one of the groups; 40 patients completed the trial. They were followed for 28 days and evaluated periodically with the BPRS, Negative Symptoms Rating Scale, Simpson Angus Extrapyramidal Rating Scale and UKU rating scale. Hormonal concentrations (estradiol, estrone, progesterone, FSH, LH and prolactine) were measured at baseline and weekly throughout the trial. Both groups showed similar clinical improvement during the evaluation, although there was a trend for the CE group to show a better improvement than the placebo group (p < 0.10). Side effects and the use of anticholinergics were similar in both groups. Conjugated estrogens caused elevation only of estrone levels in the CE group; estradiol and prolactin showed a similar profile for both groups. Our negative findings regarding the antipsychotic effect of conjugated estrogens does not preclude, however, a possible efficacy of other estrogens, such as 17-beta-estradiol, in schizophrenia.

Acute Disease↗